Diabetic Neuropathic Pain - Pipeline Review, H1 2014

  • Share on Google+

Global Markets Direct

2014 Jun 30

107 Pages (PDF)




Diabetic Neuropathic Pain - Pipeline Review, H1 2014

Summary

Global Markets Directs, Diabetic Neuropathic Pain - Pipeline Review, H1 2014, provides an overview of the Diabetic Neuropathic Pains therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathic Pain and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathic Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Diabetic Neuropathic Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Diabetic Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Diabetic Neuropathic Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathic Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Diabetic Neuropathic Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 8
Global Markets Direct Report Coverage 8
Diabetic Neuropathic Pain Overview 9
Therapeutics Development 10
Pipeline Products for Diabetic Neuropathic Pain - Overview 10
Pipeline Products for Diabetic Neuropathic Pain - Comparative Analysis 11
Diabetic Neuropathic Pain - Therapeutics under Development by Companies 12
Diabetic Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 15
Diabetic Neuropathic Pain - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Diabetic Neuropathic Pain - Products under Development by Companies 19
Diabetic Neuropathic Pain - Products under Investigation by Universities/Institutes 20
Diabetic Neuropathic Pain - Companies Involved in Therapeutics Development 21
Bristol-Myers Squibb Company 21
AstraZeneca PLC 22
Eli Lilly and Company 23
BioDelivery Sciences International, Inc. 24
Daiichi Sankyo Company, Limited 25
Acorda Therapeutics, Inc. 26
Astellas Pharma Inc. 27
Glenmark Pharmaceuticals Ltd. 28
KunWha Pharmaceutical Co., Ltd. 29
Mertiva AB 30
Grunenthal GmbH 31
Bial - Portela & Ca, S.A. 32
Relmada Therapeutics, Inc. 33
Sphaera Pharma Pvt. Ltd. 34
SK Biopharmaceuticals Co., Ltd. 35
Immune Pharmaceuticals, Inc. 36
AbbVie Inc. 37
Dong-A Socio Holdings Co Ltd 38
Diabetic Neuropathic Pain - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Target 41
Assessment by Mechanism of Action 44
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
duloxetine hydrochloride DR - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
capsaicin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
(amitriptyline + ketamine) - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
clonidine hydrochloride - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
eslicarbazepine acetate - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
pregabalin ER - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
SKL-NP - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
cebranopadol - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
AZD-5213 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
GRC-17536 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
mirogabalin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
BMS-954561 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ABT-639 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
DA-9801 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
ibudilast - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Dextromethadone - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
SPC-612 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
NG2-GAD - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
mepivacaine hydrochloride - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Peptide for Methylglyoxal Induced Pains - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
PGN-305 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
AS-1069562 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
PRTT-200 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Diabetic Neuropathic Pain - Recent Pipeline Updates 82
Diabetic Neuropathic Pain - Dormant Projects 98
Diabetic Neuropathic Pain - Discontinued Products 99
Diabetic Neuropathic Pain - Product Development Milestones 100
Featured News & Press Releases 100
Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab 100
Sep 06, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt 100
Sep 03, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis 101
Aug 14, 2013: Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz 101
Oct 30, 2012: Drug Offers New Pain Management Therapy For Diabetics, Study Finds 102
Aug 29, 2012: Janssen Receives FDA Approval For Nucynta Extended-release Oral Tablets For Management Of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy 102
Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program 103
Mar 20, 2012: Astellas Pharma Europe Withdraws Its Applications For Extension Of Indication For Qutenza 104
Feb 22, 2012: Shionogi And Lilly Japan Announce Approval Of Additional Indication For Cymbalta In Japan 104
Feb 08, 2012: Avanir Announces Publication Of Phase III Study Results Of AVP-923 To Treat Diabetic Neuropathic Pain 105
Appendix 106
Methodology 106
Coverage 106
Secondary Research 106
Primary Research 106
Expert Panel Validation 106
Contact Us 107
Disclaimer 107
Bristol-Myers Squibb Company
AstraZeneca PLC
Eli Lilly and Company
BioDelivery Sciences International, Inc.
Daiichi Sankyo Company, Limited
Acorda Therapeutics, Inc.
Astellas Pharma Inc.
Glenmark Pharmaceuticals Ltd.
KunWha Pharmaceutical Co., Ltd.
Mertiva AB 
Grunenthal GmbH
Bial - Portela & Ca, S.A.
Relmada Therapeutics, Inc.
Sphaera Pharma Pvt. Ltd.
SK Biopharmaceuticals Co., Ltd.
Immune Pharmaceuticals, Inc.
AbbVie Inc. 
Dong-A Socio Holdings Co Ltd				
Full Name
Email
Job Title
Mobile
Your Requirement
Full Name
Email
Job Title
Mobile
Your Requirement